Use of cilostazol for secondary stroke prevention: An old dog with New Tricks?;Uso de cilostazol para prevención secundaria de apoplejía: ¿un viejo perro con Nuevos Trucos?

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 394-402

  Ansara, Alexander J ^a   Shiltz, Dane L ^a   Slavens, Jennifer B ^b  

^a BUTLER UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acetylsalicylic acid; Aspirin; Cilostazol; Hemorrhagic stroke; Intracranial hemorrhage; Ischemic stroke; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO;

ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EPISTAXIS; EVALUATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART PALPITATION; HEMATURIA; HUMAN; LOW DRUG DOSE; MEDLINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; STROKE; TACHYCARDIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE; TETRAZOLES;

EID: 84858027237     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q420     Document Type: Review

References (43)

1. Roger VL, Go AS, Lloyd-Jones D, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209. DOI 10.1161/CIR.0b013e3182009701.
2. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76. DOI 10.1161/STR.0b013e3181f7d043.
3. Serebruany VL, Steinbuhl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218-22. DOI 10.1016/j.amjcard.2005.01.049.
4. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20. DOI 10.1016/S0140-6736(89)92327-1.
5. Package insert. Plavix (clopidogrel). Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, February 2011.
6. Package insert. Aggrenox (aspirin/extended-release dipyridamole). Ridgefield, CT: Boehringer Ingelheim, January 2011.
7. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherscler Supp 2006;6:3-11. DOI 10.1016/j.atherosclerosissup.2005.09.002.
8. Package insert. Pletal (cilostazol). Rockville, MD: Otsuka America Pharmaceutical, Inc., 2007.
9. Liu Y, Shakur Y, Yoshitake M, Kambayashi J. Cilostazol (Pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-86. DOI 10.1111/j.1527-3466.2001.tb00076.x.
10. Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-302. DOI 10.2174/1381612033453910.
11. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non-inferiority trial. Lancet Neurol 2010;9:959-68. DOI 10.1016/S1474-4422(10)70198-8.
12. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter doubleblind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-6. DOI 10.1161/01.STR.0000157667.06542.b7.
13. Kai Y, Watanabe M, Morioka M, et al. Cilostazol improves symptomatic intracranial artery stenosis-evaluation of cerebral blood flow with single photon emission computed tomography. Surg Neurol Int 2011;2:8-15. DOI 10.4103/2152-7806.76145.
14. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-57. DOI 10.1053/jscd.2000.7216.
15. Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol 2008;7:494-9. DOI 10.1016/S1474-4422(08)70094-2
16. Centers for Disease Control and Prevention. Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke: United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54:113-7.
17. Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. National Center for Health Statistics. Vital Health Stat 10 2010;Dec(249):1-207.
18. Jiang B, Wang WZ, Chen HL, et al. Incidence and trends of stroke and its subtypes in China. Stroke 2006;37:63-8. DOI 10.1161/01.STR.0000194955.34820.78.
19. Zhang LF, Yang J, Hong Z, et al. Proportion of different subtypes of stroke in China. Stroke 2003;34:2091-6. DOI 10.1161/01.STR.0000087149.42294.8C
20. Libman RB, Sacco RL, Shi T, et al. Neurological improvement in pure motor hemiparesis: implications for clinical trials. Neurology 1992;42: 1713-6.
21. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005;6:33-40. DOI 10.1016/j.atherosclerosissup.2005.09.003.
22. Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988;36:313-20. DOI 10.1159/000138400.
23. Kimura Y. Selective type III phosphodiesterase inhibitor as an antithrombotic agent. Nippon Yakurigaku Zasshi 1995;106:205-16. DOI 10.1254/fpj.106.205.
24. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-41. DOI 10.1161/01.STR.30.8.1538.
25. Wilson JTL, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin scale. Stroke 2002;33:2243-6. DOI 10.1161/01.STR.0000027437.22450.BD.
26. Kumasaka N, Sakuma M, Shirato K. Incidence of pulmonary thromboembolism in Japan. Jpn Circ J 1999;63:439-41. DOI 10.1253/jcj.63.439.
27. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention cooperative study group. Stroke 2000;31:817-21. DOI 10.1161/01.STR.31.4.817.
28. Antithrombotic Trialist' collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
29. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Longterm risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community stroke project. Stroke 1994;25:333-7. DOI 10.1161/01.STR.25.2.333.
30. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organization of services. BMJ 2004;328:326-8. DOI 10.1136/bmj.37991.635266.44.
31. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13. DOI 10.1016/S0022-510X(96)00308-5.
32. CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39. DOI 10.1016/S0140-6736(96)09457-3.
33. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, doubleblind, placebo-controlled trial. Lancet 2004;364:331-7. DOI 10.1016/S0140-6736(04)16721-4.
34. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238-51. DOI 10.1056/NEJMoa0805002.
35. ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPIRIT): randomized controlled trial. Lancet 2006;367:1665-73. DOI 10.1016/S0140-6736(06)68734-5.
36. Chinese Acute Stroke trial (CAST) collaborative group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997;349:1641-9. DOI 10.1016/S0140-6736(97)04010-5.
37. International Stroke Trial Collaborative group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349:1569-81. DOI 10.1016/S0140-6736(97)04011-7.
38. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebocontrolled randomized trials. J Stroke Cerobrovasc Dis 2009;18:482-90. DOI 10.1016/j.jstrokecerebrovascdis.2009.07.010.
39. Shinohara Y, Yamaguchi T. Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke 2008; 3:55-62. DOI 10.1111/j.1747-4949.2008.00178.x.
40. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
41. Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008;26: 63-70.
42. Cruz-Flores S, Rabinstein A, Biller J, et al. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2091-116. DOI 10.1161/STR.0b013e3182213e24.
43. Lee Y-S, Bae H-J, Kang D-W, et al. Cilostazol in acute ischemic stroke treatment (CAIST trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011;32:65-71. DOI 10.1159/000327036.